Palbociclib for Hormone Receptor-positive Breast Cancer

A phase 2 study finds that an inhibitor of CDK-4 and CDK-6 reduced the risk of disease progression by 51%.

Does Palliative Chemotherapy Really Palliate?

Many patients believe that palliative chemo is curative treatment, so oncologists need to have important end-of-life discussions early in the course of cancer care.

Enter Our April Contest and Win A Nike Fuel Band!

Become an Oncology Practice Pro by participating in this month's contest. Three lucky participants will win a Nike Fuel Band!

Update on Supreme Court Gene Patent Ruling

Questions remain regarding the sequence-interpreting experience of the new crop of BRCA testing labs.

Streptococcus bovis and CRC

Presence of a particular biotype of the Streptococcus bovis bacterium can be an indicator of a GI malignancy.

SYLATRON® (peginterferon alfa-2b)

Review slide-by-slide drug information for SYLATRON® (peginterferon alfa-2b) for treatment of melanoma.

Featured Videos

Latest News

Arzerra Plus Chlorambucil Gets FDA Nod

The FDA has approved a new indication for Arzerra to use in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia.

Volasertib Designated Orphan Drug for AML

The FDA has granted Orphan Drug designation to volasertib (Boehringer Ingelheim) for acute myeloid leukemia (AML).

AbbVie Initiates Veliparib Trial for NSCLC

AbbVie announced the initiation of a Phase 3 trial evaluating the safety and efficacy of veliparib in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer.

Viewpoints & Cases

Combo Therapy Better for Chemo-induced Nausea and Vomiting

Combo Therapy Better for Chemo-induced Nausea and Vomiting

Palonosetron and netupitant combo showed superior efficacy in controlling nausea and vomiting compared with palonosetron alone.

Ceritinib Demonstrates Strong Response in ALK-positive NSCLC

Ceritinib Demonstrates Strong Response in ALK-positive NSCLC

In a phase 1 study, the potent ALK inhibitor shows promise for treating NSCLC.

A 58-year-old with Stage IV Pancreatic Adenocarcinoma

A 58-year-old with Stage IV Pancreatic Adenocarcinoma

Chief Complaint

R.M. is a 58-year-old male recently diagnosed with stage IV pancreatic adenocarcinoma (Slide 1). He is a mechanical engineer ...

A 55-year-old Woman with Breast Cancer and Shortness of Breath

A 55-year-old Woman with Breast Cancer and Shortness of Breath

Chief Complaint

J.W. is a 55-year-old woman recently admitted to the hospital for worsening shortness of breath (Slide 1).

Relevant Medical History

• ...

From the Board

Expert Perspectives on Breast Cancer Awareness Month

Editorial Board Member Don Dizon, MD, answers some questions about issues in breast cancer treatment today.

Reflections on Patient Perspectives and Survivorship from the 2013 Breast Cancer Symposium Editorial Board Member Don S. Dizon discusses survivorship issues from the 2013 Breast Cancer Symposium.

Editorial Advisory Board


Barbara Ann Burtness, MD

Steven Cohen, MD

E. David Crawford, MD

Don S. Dizon, MD, FACP

Jeffrey M. Farma, MD

Edith A. Perez, MD

Neal D. Shore, MD, FACS

Mark A. Socinski, MD

Martin Tallman, MD

Click here for complete profiles

Poll Question

News from Oncology Nurse Advisor

Sign Up for Free e-newsletters

Enter Our April Contest

Start the contest today

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs